PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Head and neck cancers are among the most difficult to treat. They can be aggressive and are located near some of the body's ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

Vietnam Head and Neck Cancer Diagnostics Market Key Takeaways: The Vietnam head and neck cancer diagnostics market are witnessing significant growth attributed to several factors. The increasing ...

Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device ...